We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+65.27%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$5.03B
AUM Growth
+$1.32B
Cap. Flow
-$125M
Cap. Flow %
-2.48%
Top 10 Hldgs %
53.64%
Holding
139
New
31
Increased
25
Reduced
19
Closed
25

Top Buys

Rank Stock Value
1
KRRO icon
Korro Bio
KRRO
+$47.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$34M
3
ANAB icon
AnaptysBio
ANAB
+$23.6M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$20.7M
5
ZGNX
Zogenix, Inc.
ZGNX
+$20.4M

Top Sells

Rank Stock Value
1
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$104M
2
SLDB icon
Solid Biosciences
SLDB
+$69.8M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$46.8M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$36.4M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$33.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.17%
2 Financials 0.38%
3 Technology 0.12%
4 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABEO icon
76
Abeona Therapeutics
ABEO
$355M
$4.91M 0.1%
+60,000
New +$4.23M
TWST icon
77
Twist Bioscience
TWST
$5.32B
$4.53M 0.09%
215,856
+70,000
+48% +$1.64M
GRCE
78
Grace Therapeutics
GRCE
$33.8M
$4.36M 0.09%
37,081
– –
GRTX
79
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$4.28M 0.09%
+325,000
New +$3.96M
ATEC icon
80
Alphatec Holdings
ATEC
$1.48B
$3.98M 0.08%
561,574
-288,426
-34% -$1.85M
RYTM icon
81
Rhythm Pharmaceuticals
RYTM
$7.31B
$3.92M 0.08%
+170,859
New +$3.8M
TBIO
82
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$3.54M 0.07%
435,000
– –
TXMD icon
83
TherapeuticsMD
TXMD
$23.8M
$2.65M 0.05%
+21,922
New +$3.15M
EIGR
84
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.08M 0.04%
4,663
– –
ARWR icon
85
Arrowhead Research
ARWR
$12.1B
$1.95M 0.04%
30,738
– –
PHR icon
86
Phreesia
PHR
$689M
$1.86M 0.04%
+70,000
New +$1.93M
XBI icon
87
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$1.56M 0.03%
1,000,000
+100,000
+11% +$8.65M
AXNX
88
DELISTED
Axonics, Inc. Common Stock
AXNX
$1.52M 0.03%
+55,000
New +$1.31M
AORT icon
89
Artivion
AORT
$1.34B
$1.35M 0.03%
50,000
– –
SWAV
90
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$1.32M 0.03%
+30,000
New +$1.11M
KPTI icon
91
Karyopharm Therapeutics
KPTI
$155M
$1.05M 0.02%
3,643
– –
RACE icon
92
Ferrari
RACE
$67.8B
$1.03M 0.02%
6,200
– –
SIC
93
DELISTED
Select Interior Concepts, Inc. Class A Common Stock
SIC
$945K 0.02%
105,105
-334,895
-76% -$3.56M
SRRA
94
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$910K 0.02%
66,655
– –
DCPH
95
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$892K 0.02%
+14,326
New +$681K
DRNA
96
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$804K 0.02%
+36,496
New +$734K
NVCR icon
97
NovoCure
NVCR
$1.76B
$800K 0.02%
9,489
– –
ZYNE
98
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$790K 0.02%
200,000
– –
MREO
99
Mereo BioPharma
MREO
$48.9M
$588K 0.01%
179,419
– –
OPTN
100
DELISTED
OptiNose
OPTN
$535K 0.01%
+3,867
New +$502K
2 3
4
5 6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, Perceptive Advisors held 139 positions worth $5.03B, up 36% from $3.71B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Perceptive Advisors's Q4 2019 filing shows 31 new, 25 increased, 19 reduced and 25 closed positions. Its largest new stake was Korro Bio: 60,686 shares worth $49.8M. The largest sale was Dova Pharmaceuticals, Inc. Common Stock, an estimated $104M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Financials and Technology.

  • Perceptive Advisors's largest Q4 2019 buy was Korro Bio: 60,686 shares worth $49.8M.
  • Perceptive Advisors added most to Quotient Limited Ordinary Shares in Q4 2019, an estimated $20.7M increase.
  • Perceptive Advisors's biggest Q4 2019 reduction was Neurocrine Biosciences, cutting an estimated $46.8M.
  • Perceptive Advisors fully exited Dova Pharmaceuticals, Inc. Common Stock in Q4 2019, selling an estimated $104M.
  • Perceptive Advisors's ten largest holdings make up 54% of its $5.03B portfolio in Q4 2019.
  • Perceptive Advisors opened 31 new positions and closed 25 in Q4 2019.
  • Perceptive Advisors's portfolio value rose 36% quarter-over-quarter to $5.03B.

Based on Perceptive Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.